CIK 0001798749
- Emerging growth company
Jade Biosciences, Inc.
Sign in to watch- Ticker
- JBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831377888
- Phone
- +1 781-312-3013
- Business address
- 221 CRESCENT ST., BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aerovate Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 84 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-05 | Santel Donald J Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2024-06-05 | Resnick Joshua Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2024-06-05 | Katabi Maha Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2024-06-05 | Iwicki Mark T Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2024-06-05 | GRAYZEL DAVID S. Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2024-06-05 | Dable Habib J Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2024-06-05 | Dorval Allison Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2024-05-17 | Gillies Hunter CHIEF MEDICAL OFFICER | Option exercise 10b5-1 | +4,000 | $2.14 | $9K | 9,602 |
| 2024-05-17 | Gillies Hunter CHIEF MEDICAL OFFICER | Sale 10b5-1 | −3,914 | $21.07 | $82K | 5,688 |
| 2024-05-17 | Gillies Hunter CHIEF MEDICAL OFFICER | Sale 10b5-1 | −86 | $21.86 | $2K | 5,602 |
| 2024-05-17 | Gillies Hunter CHIEF MEDICAL OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,000 | 11,324 | ||
| 2024-05-16 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 | +10,000 | $2.14 | $21K | 10,000 |
| 2024-05-16 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −8,707 | $21.52 | $187K | 1,293 |
| 2024-05-16 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −1,293 | $21.92 | $28K | 0 |
| 2024-05-16 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,000 | 343,381 | ||
| 2024-05-02 | Verwijs Marinus CHIEF TECHNICAL OFFICER | Sale | −1,981 | $21.02 | $42K | 0 |
| 2024-05-01 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 | +10,000 | $2.14 | $21K | 10,000 |
| 2024-05-01 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −9,035 | $20.34 | $184K | 965 |
| 2024-05-01 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −965 | $20.87 | $20K | 0 |
| 2024-05-01 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −1,357 | $19.91 | $27K | 0 |
Page 3 of 16 · 315 trades